CYTK CEO Robert Blum Exercises Options, Sells 7,500 Shares

What Happened

• Robert I. Blum, President & CEO and a director of Cytokinetics, exercised 7,500 stock options and acquired 7,500 common shares at $10.60 per share (cost $79,500) on 2026-08-31. He then sold those 7,500 shares in an open-market sale the same day at $70.24 per share, generating proceeds of $526,800. The filing also shows a derivative disposition of 7,500 units at $0.00, reflecting the conversion/settlement of the exercised options.

Key Details

• Transaction date: 2026-08-31
• Exercise: 7,500 shares @ $10.60 = $79,500 (code M)
• Sale: 7,500 shares @ $70.24 = $526,800 (code S)
• Net proceeds before fees/taxes: approximately $447,300 (proceeds minus exercise cost)
• Shares owned after transaction: not specified in this filing; footnotes indicate shares held by The Bridget Blum 2003 Irrevocable Trust (F1) and The Brittany Blum 2003 Irrevocable Trust (F2)
• No 10b5-1 plan or late filing flag disclosed in this Form 4

Context

• This was a same-day exercise and sale (commonly a “cashless exercise” pattern), meaning options were exercised and the resulting shares were immediately sold. Such transactions are often used to cover exercise costs, tax withholding, or to realize gains and are fairly routine for insiders. The filing is factual and does not state the insider’s motivation.